Stockreport

BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study

BriaCell Therapeutics Corp. - Common Shares  (BCTX) 
PDF Phase 1/2 dose escalation study to evaluate BriaCell’s personalized next generation immunotherapy treatment in metastatic breast cancerBria-OTS™ to be studied as monothe [Read more]